AI and healthcare in Switzerland: opportunities, risks and best practices

AI in healthcare: what are we talking about?

Artificial intelligence applied to healthcare brings together the machine-learning technologies used to assist medical diagnosis, accelerate clinical research, optimise hospital management and personalise care pathways. In Switzerland, this field is growing rapidly, driven by a solid innovation ecosystem and a world-leading pharmaceutical sector.

Switzerland positions itself as a European hub for AI in healthcare, with institutions such as EPFL, ETH Zurich and the Swiss AI Center producing cutting-edge research. Beyond research, how can field players (clinics, hospitals, medical practices) tap into these advances?

The Swiss health-tech ecosystem in figures

The Swiss digital health market is estimated at more than CHF 2.3 billion in 2025, with annual growth of around 15 to 20%. Several structural factors fuel this dynamic:

• More than 350 health-tech start-ups are active in Switzerland, mainly concentrated in the cantons of Zurich, Vaud and Basel
• The Swiss Personalized Health Network (SPHN) coordinates the secure sharing of clinical data between university hospitals, creating a database that can be used by AI at national scale
• The high medical density (4.4 doctors per 1,000 inhabitants, against an OECD average of 3.7) provides favourable adoption ground, with professionals trained and aware of digital tools
• Health R&D investments represent around CHF 12 billion per year, of which a growing share is oriented towards AI and machine learning

Initiatives such as Health Valley (Lake Geneva region) and Basel Area Business & Innovation position Switzerland as an international crossroads between pharma, medtech and artificial intelligence.

Concrete opportunities

AI-assisted diagnosis

AI excels at medical image analysis. In radiology, algorithms now achieve detection rates comparable to those of specialists for certain pathologies:

• Thoracic imaging: detection of pulmonary nodules with sensitivity above 95%
• Dermatology: classification of skin lesions with precision rivalling experienced dermatologists
• Ophthalmology: screening for diabetic retinopathy from fundus photographs

These tools do not replace the doctor; they support them. They act as an automated second opinion, reducing the risk of error and accelerating diagnosis time. In time, this capacity for AI personalisation could transform the patient journey end to end.

Accelerated clinical research

AI transforms clinical research at several levels:

• Identifying candidates for clinical trials: algorithms analyse patient files to identify those matching inclusion criteria, reducing recruitment time by 30 to 50%
• Scientific literature analysis: LLMs can synthesise thousands of articles in a few hours, identifying patterns that humans would take weeks to spot
• Drug discovery: AI accelerates the identification of candidate molecules, an area where Swiss companies such as Novartis and Roche invest massively

Optimised administrative management

The administrative side absorbs a significant share of medical time. AI can help reduce this load:

• Automated medical transcription: conversion of oral consultations into structured reports
• Automatic coding: assignment of diagnostic codes (ICD-10) from clinical notes
• Smart scheduling: optimisation of agendas, beds and hospital resources

For a medium-sized Swiss clinic, administrative automation can free up the equivalent of several hours per doctor per week.

Telemedicine and remote monitoring

Telemedicine has accelerated significantly since 2020. In Switzerland, more than 30% of primary-care consultations now include a digital component (video, secure messaging, remote monitoring). AI enriches these practices:

• Smart triage: medical chatbots route patients to the right level of care even before the consultation, reducing unnecessary emergency visits by 15 to 25%
• Continuous monitoring: connected devices (glucose sensors, blood-pressure monitors, oximeters) transmit data analysed in real time by algorithms that detect anomalies and alert the doctor
• Post-operative follow-up: AI-driven applications track patient recovery at home, reducing readmissions

Swiss players such as Medgate, Soignez-moi.ch and eedoctors are progressively integrating these AI layers into their platforms.

The risks to manage

Algorithmic bias

AI models are trained on historical data that can reflect existing biases. In healthcare, this can translate into:

• Algorithms that perform less well for certain populations under-represented in training data
• Treatment recommendations biased by historically unequal practices
• Over-confidence in automated predictions

Vigilance against bias is particularly important in the multicultural Swiss context, where the diversity of patient profiles is significant.

Confidentiality and FADP

The Federal Act on Data Protection (FADP), revised in September 2023, imposes strict requirements on health-data processing, considered sensitive data requiring a heightened level of protection.

The main points of vigilance:

• Informed consent: patients must be informed of AI use in their care pathway
• Data minimisation: only strictly necessary data may be processed
• Localisation: prefer hosting data in Switzerland, ideally with certified providers
• Right to explanation: patients can request to understand how a decision concerning them was made by an algorithm

Data sovereignty: a central issue

Beyond the FADP, the question of health data sovereignty is taking on strategic importance in Switzerland. The main concerns:

• Dependence on American clouds: most AI solutions in healthcare rely on AWS, Azure or Google Cloud. The extraterritorial application of the US CLOUD Act poses a legal risk for sensitive data hosted with these providers
• Sovereign alternatives: Swiss providers such as Infomaniak, Exoscale and Open Systems offer cloud infrastructures certified and domiciled in Switzerland, compatible with FADP requirements
• Federated learning: this approach allows AI models to be trained without centralising patient data. Each hospital keeps its data locally; only model parameters are shared. The SWISSFL project, led by several university hospitals, explores this path

For healthcare establishments, the choice of hosting infrastructure is not just a technical question: it is a matter of patient trust and regulatory compliance.

Medical responsibility

The question of liability in the event of an error by a diagnostic algorithm remains legally complex in Switzerland. If a doctor follows the recommendation of an AI that proves to be wrong, who is responsible? The doctor, the software publisher, the hospital?

The current majority position is that the doctor remains the final decision-maker and retains clinical responsibility. AI is a decision-support tool, not an autonomous decision-maker.

The Swiss and European regulatory framework

Switzerland navigates between its own legal framework and the influence of the EU AI Act, which has been progressively coming into force since 2024. Medical devices integrating AI are classified as "high-risk" and subject to stricter requirements.

Swiss companies exporting to the EU must comply with both regulatory frameworks. In practice, this means:

• Exhaustive technical documentation of the algorithms used
• Conformity assessments by notified bodies
• A risk management system across the full product lifecycle
• Continuous post-market surveillance

Swissmedic, the Swiss authority for therapeutic products, is working to align its requirements with international standards while preserving the specifics of the Swiss healthcare system.

Implications for Swiss businesses

The adoption of AI in healthcare does not only concern hospitals and medtech start-ups. It affects a wide range of economic players:

• Health insurers: predictive models help identify patients at risk of chronic diseases and propose targeted prevention programmes. Several Swiss health insurers are already testing behavioural-analysis tools to optimise their offerings
• Consultancies and IT integrators: demand for strategic support (solution choice, regulatory compliance, change management) is growing rapidly. Mandates linked to AI in healthcare represent a promising market segment. Recruiting AI talent remains a major challenge in this sector
• Pharmaceutical industry: beyond drug discovery, AI optimises pharmacovigilance, supply chain and treatment personalisation. The Swiss sites of Novartis, Roche and Lonza integrate these technologies into their industrial processes
• Medtech SMEs: Swiss medical device manufacturers must integrate EU AI Act requirements into their development cycle. Specialised support is often necessary to navigate this regulatory complexity

The key to success lies in a pragmatic approach: identify high value-added use cases, secure compliance from design, and continuously train teams.

How Swiss players can prepare

1. Start with administrative tasks: automating administrative tasks (transcription, coding, scheduling) offers fast ROI with limited regulatory risk
2. Train medical teams: understanding AI's capabilities and limits is essential for responsible adoption
3. Choose certified partners: prefer solutions with recognised medical certifications (CE, FDA)
4. Anticipate regulation: integrate EU AI Act requirements from the design stage, even for projects targeting only the Swiss market

FAQ

Can AI replace a doctor in Switzerland?

No. Swiss regulation and the position of the FMH (Federation of Swiss Doctors) are clear: AI is a decision-support tool. Final diagnosis, prescription and clinical responsibility remain the exclusive domain of the doctor. The most advanced AI solutions are designed to augment the practitioner's capabilities, not to replace their judgement.

What health data can be used to train an AI model in Switzerland?

The FADP classifies health data as sensitive. Its use for research or model-training purposes requires either explicit patient consent or irreversible anonymisation of the data. Cantonal ethics committees must validate research protocols involving patient data. These governance issues tie into the broader reflection on AI and responsible digital. The SPHN provides a governance framework for inter-institutional sharing of this data.

What budget should I plan for a first AI project in healthcare?

A pilot project for administrative automation (transcription, coding) can start with a budget of CHF 20'000.– to CHF 50'000.–, deployment included. Assisted-diagnosis projects are more complex and generally require an investment of CHF 100'000.– to CHF 300'000.–, regulatory certification included. In all cases, a prior audit of the organisation's needs and data maturity is recommended before any budget commitment.

Operational summary

• AI is transforming Swiss healthcare in three areas: assisted diagnosis, clinical research and administrative management.
• The main risks are algorithmic biases, data confidentiality (FADP) and medical responsibility.
• The Swiss regulatory framework is progressively aligning with the EU AI Act, classifying medical AI devices as "high-risk".
• The recommended approach: start with administrative tasks, then progressively extend to clinical use cases.
• Contact MCVA Consulting to assess AI opportunities in your healthcare organisation.

Want to explore AI's potential for your healthcare establishment or medtech company? MCVA Consulting supports Swiss healthcare players in identifying use cases, regulatory framing and the deployment of AI solutions. Get in touch with our team for an initial no-obligation conversation.